SCHEMBL13484516

SCHEMBL13484516

CC(C)C(=O)C(C)CN1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.51
ADRA2B P18089 2/20 0.51
DRD3 P35462 2/20 0.51
SIGMAR1 Q99720 2/20 0.51
HRH3 Q9Y5N1 2/20 0.51
ALDH1A1 P00352 4/20 0.50
LMNA P02545 1/20 0.50
CYP2D6 P10635 1/20 0.49
ADRA2C P18825 1/20 0.49
CHRM3 P20309 1/20 0.49
OPRD1 P41143 1/20 0.49
KCNH2 Q12809 1/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 3/20 0.44
HPGD P15428 1/20 0.44
ANPEP P15144 1/20 0.41
ERAP2 Q6P179 1/20 0.41
CHRM1 P11229 1/20 0.41
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL499912 0.81 ALDH1A1 (0.63) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL13484776 0.81 CHRM1 (0.55) CHRM2ADRA2BDRD3SIGMAR1HRH3
Hydrochloric Acid SCHEMBL19815486 0.79 ALDH1A1 (0.67) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL21748901 0.79 CHRM2 (0.51) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL500486 0.78 ALDH1A1 (0.66) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL12123730 0.78 CHRM1 (0.56) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL20749891 0.78 CHRM2 (0.51) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL30017355 0.77 CHRM2 (0.49) CHRM2ADRA2BDRD3SIGMAR1HRH3
Hydrochloric Acid SCHEMBL5087977 0.77 ALDH1A1 (0.69) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL9774559 0.76 CHRM2 (0.49) CHRM2ADRA2BDRD3SIGMAR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 CHRM2 2255/4885ADRA2B 1974/4885DRD3 1966/4885
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 CHRM2 2255/4885ADRA2B 1974/4885DRD3 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.